The COVID-19 pandemic underscored the critical role of blood coagulation testing in managing complex health conditions. Patients with severe COVID-19 often developed abnormal clotting (thrombosis) or bleeding disorders, requiring urgent coagulation assessments. This experience accelerated demand for coagulation testing, as healthcare systems worldwide recognized the need for proactive monitoring, especially for high-risk populations. Post-pandemic, this demand shows no signs of slowing, with the market continuing to benefit from heightened awareness of clotting risks.

Pandemic-related demand surged in 2021. Global sales of coagulation testing devices rose by 40% that year, driven by emergency departments and ICUs testing COVID-19 patients for PT, aPTT, and D-dimer levels (a marker of clot breakdown). Even as pandemic severity decreased, demand remained elevated. In 2023, 65% of hospitals reported maintaining increased coagulation testing protocols for post-COVID patients, particularly those with long-term conditions like lung damage or cardiovascular issues. This shift has made coagulation testing a routine part of post-acute care, boosting market growth.

Home testing kits also saw a surge. With patients hesitant to visit clinics, at-home coagulation tests—like those for INR monitoring—grew by 50% globally between 2020 and 2023. These kits, often paired with mobile apps, allow users to self-collect samples and share results with doctors remotely. In Europe, where telehealth adoption accelerated during the pandemic, 40% of anticoagulant users now prefer home testing, citing convenience and reduced exposure risks.

The post-pandemic legacy for coagulation testing is enduring. As healthcare systems prioritize preparedness for future outbreaks, investments in diagnostic capacity—including coagulation testing—are rising. For businesses, this presents an opportunity to innovate in areas like rapid, multi-parameter tests. Resources detailing post-pandemic trends in blood coagulation testing offer insights into sustained demand drivers, user preferences, and clinical integration needs. By capitalizing on this momentum, the market can continue to evolve and support global health resilience.